Piramal Pharma Allots 21 Lakh Equity Shares to Employee Welfare Trust Under ESOP Scheme
Piramal Pharma Ltd has allotted 21,00,000 equity shares to the Piramal Pharma Limited Employees Welfare Trust (ESOP Trust) on June 5, 2026. This allotment is made under the framework of the Piramal Pharma Limited - Employee Stock Option and Incentive Plan - 2022 (ESOP Scheme).The ESOP Trust received these equity shares at a face value of Rs. 10/- each. The shares allotted to the Trust are designated for transfer to Eligible Employees upon them exercising their Options under the ESOP Scheme.
This allotment has resulted in an increase in the paid-up share capital of the Company. Prior to this issue, the paid-up capital stood at Rs. 1,329,24,81,300, comprising 132,92,48,130 equity shares of face value Rs. 10/- each. Following the allotment, the paid-up share capital has increased to Rs. 1,331,34,81,300, corresponding to a total of 133,13,48,130 equity shares of face value Rs. 10/each.
Details regarding the issued security and resulting capitalization are summarized below:
| Metric | Pre-Allotment Status | Post-Allotment Status |
|---|---|---|
| Paid-up Share Capital | Rs. 1,329,24,81,300 | Rs. 1,331,34,81,300 |
| Total Equity Shares | 132,92,48,130 | 133,13,48,130 |
| Shares Allotted in this Issue | N.A. | 21,00,000 |
The shares allotted to the ESOP Trust have been designated to rank pari passu with all existing shares of Piramal Pharma Ltd.
PPLPHARMA Stock Price Movement
Today, shares of Piramal Pharma Limited shed value in the closed market, settling down 1.80% and closing at ₹166.77. The stock traded within a range between a low of ₹165.99 and a high of ₹170.9 during the session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.